Check Cap Stock Price, News & Analysis

MBody AI (NASDAQ: CHEK) announced major enterprise deployments, multi-year, multi-million-dollar contracts, and growing investor interest ahead of a merger vote on November 14, 2025 that would combine Check-Cap with MBody AI.

The release highlights the MBody AI Orchestrator as a hardware-agnostic platform deployed at Fortune 500 clients, citing up to 40% labor reduction, 80% uptime improvement, and accelerating global adoption with "hundreds of millions" in investor interest.

Check-Cap (NASDAQ: CHEK) announced it rescheduled its Annual General Meeting to November 14, 2025 and provided an update on the proposed business combination with MBody AI. The companies executed a Merger Agreement on September 12, 2025 under which Merger Sub will merge into MBody AI, making MBody AI a wholly owned subsidiary of Check-Cap, subject to shareholder approval and closing conditions.

Key transactional details: the Board affirmed the originally disclosed exchange ratio; a proposed reverse share split range of 1-for-2 to 1-for-100; authorized ordinary shares will remain at 18,000,000 with nominal value NIS 48.0; record date for voting was September 16, 2025. MBody AI reports material inbound demand and says investor inquiries reached hundreds of millions of dollars. If approved, the company plans a name change to "MBody AI Ltd." and intends cross-listing and further institutional alignment post-close.

Check-Cap (NASDAQ:CHEK) has entered into a definitive merger agreement with MBody AI, creating a combined company focused on embodied AI for the autonomous workforce. Under the agreement, MBody AI shareholders will own 90% of the combined company, while Check-Cap shareholders will retain 10% on a fully diluted basis.

The merged entity, to be renamed MBody AI Ltd., will operate in the embodied-AI market, which Morgan Stanley forecasts to reach $40 Trillion by 2050. MBody AI specializes in developing proprietary AI technology for intelligent systems, initially focusing on hospitality with plans to expand into warehousing, office management, and healthcare. Check-Cap's legacy business, including patents and proprietary medical equipment, will continue as part of the combined company.

The merger requires Check-Cap shareholder approval at the October 17, 2025 Annual General Meeting. Additionally, Check-Cap must address a Nasdaq compliance issue regarding minimum stockholders' equity by October 20, 2025.

Check-Cap Ltd. (NASDAQ: CHEK) has issued a strong condemnation against Chris Taves, Chairman of MediPharm Labs and Head of Asia for BMO Capital Markets, for allegedly making false and defamatory statements about the company. The Israeli medical diagnostics company claims Taves deliberately released misleading information on May 23, 2025, timing the release just before Shabbat to delay Check-Cap's response. The company accuses Taves of exploiting wartime circumstances in Israel and potentially violating Section 9(a)(2) of the U.S. Securities Exchange Act of 1934 by attempting to manipulate Check-Cap's stock price. Check-Cap demands an immediate retraction, cessation of misleading communications, and a public apology from both MediPharm Labs and Taves.

MediPharm Labs Corp. (TSX: LABS) has filed proxy materials for its June 16, 2025 Annual and Special Meeting, facing a proxy battle with dissident shareholder Apollo Technology Capital Corp. The company reported strong 2024 performance with 27% year-over-year revenue growth and improved gross margins of 31% (up from 18% in 2023). The company's Adjusted EBITDA loss narrowed by $8.3M to $1.9M in 2024. Under CEO David Pidduck's leadership since 2022, MediPharm has transformed through strategic initiatives, including the successful VIVO Cannabis acquisition which doubled revenue and provided international market access. The company faces opposition from Apollo, which owns 3% of shares and is nominating six alternative board members. MediPharm's board raises concerns about Apollo's nominees, particularly regarding chairman Regan McGee's controversial business history and lack of industry experience.